RHHBY - Pfizer And Roche Advance On Their Weight Loss Drug Journeys | Benzinga
After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On Thursday, Pfizer revealed it will begin studies to evaluate the optimal dose of its weight lose pill during the second half of the year. With the new formulation, Pfizer continues its attempt to catch up to Eli Lilly and Company (NYSE: LLY) and Novo Nordisk (NYSE: NVO) who are currently dominating the weight loss drug landscape.
Pfizer Has Struggled To Catch Up To Eli Lilly And Novo Nordisk
What Eli Lilly, Novo Nordisk and Pfizer are aiming to do is provide a more convenient alternative to injections. Throughout last year, Novo Nordisk and Eli Lilly have enjoyed soaring demand for their injections, despite hefty price tags and limited insurance coverage.
Pfizer previously discontinued its twice daily version of the weight loss drug due to side effects like nausea and vomiting that resulted in high dropout rates in midstage trials. Before this particular setback, Pfizer already dropped another daily weight-loss drug ...